MDMA optimizes brain chemistry for safety, openness, and compassion. AEDP uses relational interventions to enhance MDMA's effects in trauma therapy, fostering trust, intimacy, and healing attachment.
Kari Gleiser
Veterans, First Responders, and families supporting psychedelic medicine will be honored at the conference for their mental health challenges and the urgent need for better care and resources.
Itzel Barakat, Justin LaPree
Rick Doblin reflects on 38 years of MAPS, discussing psychedelic milestones and obstacles. Lykos Therapeutics submits NDA for MDMA-assisted therapy for PTSD in December 2023.
Rick Doblin
James S. Gordon, MD, psychiatrist and author, shares how Mind-Body Skills Groups have reduced PTSD diagnoses by 80%, discussing their techniques and the potential integration of psychedelic experiences.
James Gordon
MAPS completes Phase 3 study for MDMA-AT in PTSD treatment, marking historic milestone in psychedelic drug research. Safety and efficacy of MDMA-assisted therapy still under investigation.
Keren Tzarfaty, Michael Mithoefer, Julie Holland
Stanford conducted the first trial of Magnesium-Ibogaine on Special Operations Forces Veterans with traumatic brain injury, showing significant functional improvements and high remission rates for comorbid psychiatric disorders. Further controlled
Nolan Williams
Bob Parsons, a Vietnam War veteran and entrepreneur, advocates for psychedelic therapies to address PTSD. He shares how psychedelics helped him heal and is now helping other veterans.
Bob Parsons
Families of veterans are affected by trauma, depression, and addiction. Session explores healing for families impacted by veterans' struggles.
Anne Wagner, Lauren Myers, Andrea Lucie
Catherine Oxenberg's daughter India survived a traumatic experience in the NXIVM cult, leading to long-lasting scars. The Catherine Oxenberg Foundation now supports survivors of sexual assault with ketamine-assisted psychotherapy retreats.
Vicky Dulai, Catherine Oxenberg, India Oxenberg